

Local allergic rhinitis responds to allergen immunotherapy

29 March 2016



after 12 months of AIT-DP, with negative NAPT in 50 percent of patients; significant increases were seen in serum sIgG4. Immunotherapy was well tolerated, with no reports of systemic reactions.

"This study demonstrated that AIT-DP is a safe and clinically effective treatment for LAR, confirming that LAR is a new indication for AIT," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

(HealthDay)—*Dermatophagoides pteronyssinus* (DP) subcutaneous allergen immunotherapy (AIT) seems safe and effective for local allergic rhinitis (LAR), according to a study published online March 23 in *Allergy*.

Carmen Rondón, M.D., Ph.D., from the IBIMA-Regional University Hospital of Málaga in Spain, and colleagues conducted a first randomized, double-blind, placebo-controlled phase II trial of DP-AIT in 36 LAR patients. Participants were randomized to Pangramin Plus DP or placebo for 24 months. Symptoms, medication scores, and medication-free days were assessed as primary end points. Secondary end points included skin test, serum specific immunoglobulin E (sIgE) and IgG4, nasal [allergen](#) provocation test (NAPT), and adverse events.

The researchers observed significant improvements in primary and secondary end [points](#) for AIT-DP versus placebo. A significant and marked increase was seen in allergen tolerance

APA citation: Local allergic rhinitis responds to allergen immunotherapy (2016, March 29) retrieved 23 April 2021 from <https://medicalxpress.com/news/2016-03-local-allergic-rhinitis-allergen-immunotherapy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.